EGFR and medulloblastoma: Previously, we reported drug interaction studies between the pan-ErbB inhibitor dacomitinib with CPA using these same medulloblastoma cell lines and found additive or antagonistic in vitro drug interactions were in fact antagonistic in vivo [66].